An Exploratory, Phase II Trial to Determine the Association of Lapatinib-Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 02 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 May 2013 Planned end date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.